Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Net Cash Flow (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Net Cash Flow for 11 consecutive years, with $475.9 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 2172.2% to $475.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 billion through Dec 2025, up 485.62% year-over-year, with the annual reading at $1.9 billion for FY2025, 485.62% up from the prior year.
  • Net Cash Flow for Q4 2025 was $475.9 million at BeOne Medicines, down from $1.3 billion in the prior quarter.
  • The five-year high for Net Cash Flow was $3.4 billion in Q4 2021, with the low at -$398.5 million in Q3 2021.
  • Average Net Cash Flow over 5 years is $183.9 million, with a median of -$48.7 million recorded in 2022.
  • The sharpest move saw Net Cash Flow surged 3721.64% in 2021, then crashed 815.09% in 2023.
  • Over 5 years, Net Cash Flow stood at $3.4 billion in 2021, then crashed by 111.51% to -$390.0 million in 2022, then skyrocketed by 116.11% to $62.8 million in 2023, then crashed by 136.56% to -$23.0 million in 2024, then skyrocketed by 2172.2% to $475.9 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $475.9 million, $1.3 billion, and $232.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.